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ABSTRACT

Mitragynine is a major alkaloid extracted from the leaves of the Thai traditional herb,
Mitrcigymi speciosa Korth (Rubiaceae). The extracts of this plant have been used as
substitutes for opium and recent studies have reported that mitragynine possesses
antinociceptive actions mediated via the mu opioid receptors. Nonetheless, structural
features of mitragynine do not fit the classical opiate ligands.

Thus the primary

objectives of this study were to evaluate the antinociceptive effect of mitragynine and its
synthetic analogs to determine the molecular basis of mitragynine binding to opioid
receptors in order to provide better understanding of the potential therapeutic roles of
these compounds.

The antinociceptive effect of intraperitoneal (i.p.) injection of

mitragynine (10-30 mg/kg) was investigated as compared to morphine (5-20 mg/kg)
using the tailflick and hotplate tests. In both tests, mitragynine exerted a dose-dependent
antinociceptive activity that was maximal at 30 min but was less potent than morphine.
Such effects were completely abolished by pretreatment with the opioid receptor
antagonist naloxone (10 mg/kg, i.p.).

The synthetic mitragynine analogs MC 183,

MCI86, and MC 187 exhibited no antinociceptive activity at 30 mg/kg dose (i.p.) in
either the hotplate or tailflick tests. The present study will provide better insight into the
mechanism of action of mitragynine as well as the pharmacology of opioid receptors.
Such understanding may lead to the generation of a new class of analgesics of potential
therapeutic value.
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I.

INTRODUCTION
According to the American Academy of Pain Management, nearly 50 million

Americans suffer from chronic pain caused by disease, injury, or disorder (Weiner,
2002). Furthermore, 25 million Americans suffer from acute pain due to surgery or
accident (Weiner, 2002). Some experts estimate that approximately $100 billion is spent
each year to treat pain (Wallis, 2005).
A. Pain and its Pathways
Pain is the body’s defense mechanism against stimuli that will damage its tissues,
and it is detected by sensory receptors called nociceptors. Pain triggers a reflexive
component that allows the organism to immediately remove itself from the noxious
stimuli and an emotional component that encourages the organism to avoid the behavior
that resulted in the pain. The three categories of nociceptors are mechanical, thermal, and
polymodal nociceptors (Sherwood, 2007). Once stimulated, these receptors transmit
signals to the central nervous system via two types of afferent fibers: A-delta fibers and C
fibers. The cell bodies of these fibers are located in the dorsal root ganglia and end in the
gray matter of the dorsal horn of the spinal cord, terminating on projection neurons that
transmit pain signals to higher centers of the brain.
Mechanical and thermal nociceptors transmit signals through A-delta fibers which
are large in diameter and myelinated (Meyer, 2005). The large diameter of the fibers
enables the organism to recognize the location of the noxious stimuli. The myelinated
axons allow action potentials to be conducted very quickly and results in early pain.
Early pain travels via the spinothalamic tract from the spinal cord to the
posteroventrolateral nucleus, a part of the thalamus, to the primary and then secondary
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somatosensory cortex (Sherwood, 2007). The primary somatosensory cortex provides
sensory discrimination of pain, and the secondary cortex allows for the detection of pain
and memory of previously painful experiences.
Polymodal nociceptors transmit signals through C fibers which are small in
diameter and unmyelinated.

The unmyelinated, small-diameter axons cause action

potentials to be conducted at a significantly slower rate than the action potentials of the
A-delta fibers, and this is known as late pain (Sherwood, 2007). Late pain is transmitted
via the same pathway as early pain but diverges at the thalamus, yielding additional
collaterals to various other brain structures such as the hypothalamus, amygdala, and the
anterior cingulated cortex, which plays a key role in pain affect, attention, and motor
responses (Sherwood, 2007).
B. Classes ofAnalgesics
Pain is treated with non-narcotic or narcotic analgesics. The two major classes of
the non-narcotic analgesics are paracetamol (acetaminophen) and non-steroidal anti
inflammatory drugs(NSaids)(Minneman, 2005). The narcotics consist of another class
of drugs known as the opioids, and this class includes natural narcotics, the synthetic
narcotics, and the endogenous opioids (Katzung, 1998). Both classes of drugs relieve
pain by inhibiting different components of the pain pathway previously described, and
those differences account for the effectiveness of the drug’s analgesic activity as well as
the side effects that result. The non-narcotics are effective in treating minor to moderate
pain and are associated with a few side effects. The narcotics are the most effective
painkillers known to man and are used to treat moderate to severe pain. However, the
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side effects associated with narcotics are extremely serious, ranging from nausea and
vomiting to addiction.
C Non-narcotic Analgesics
Paracetamol, an analgesic and antipyretic, is the active metabolite of phenacetin
(Stringer, 2006) and an over-the-counter drug commonly used to reduce fever and relieve
various aches and minor pains. Paracetamol can be combined with low doses of other
NSAIDs or opioid analgesics to treat more severe pain resulting in a cumulative
reduction of side effects (Bertolini, 2006). Paracetamol is the active ingredient of the
brand named dmgs Excedrin, Goody’s, and Tylenol as well as several others(NLM/NIH
Online, 2007) and it relieves pain by reducing production of prostaglandins, fatty acid
derivatives, that enhance the receptor response to noxious stimuli (Bertolini, 2006).
Paracetamol is not as potent as the NSAIDs or opiates, but comparatively, it is safer
because it does not irritate the lining of the stomach or affect blood coagulation as much
as the NSAIDs. Furthermore, paracetamol does not have high risk for addiction,
dependence, tolerance, or withdrawal, which are all side effects of opioids (Bertolini,
2006). However, frequent use of paracetamol may result in liver damage (Stringer,
2006).
Similar to paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) have
analgesic and antipyretic effects.

In addition, NSAIDs have anti-inflammatory and

antithrombotic effects (Stringer, 2006).

Because they vary in potency, duration of

action, and elimination from the body, not all NSAIDs are available over-the-counter.
They are used to treat inflammation, various types of mild to moderate aches and pains,
and fever (NLM/NIH Online, 2007). Aspirin, ibuprofen, and ketorolac are just a few of

3

the commonly used NSAIDs. Similar to paracetamol, NSADDs relieve pain by acting on
prostaglandin synthesis.

However, NSAIDs completely inhibit the production of

prostaglandins, including those which protect the lining of the stomach, and NSAIDs also
inhibit the production of thromboxanes, which support platelet aggregration. This leads
to some of the NSAIDs most serious side effects: stomach ulcers, bleeding, diarrhea, and
even kidney and liver failure (Stringer, 2006).

NSAIDs are effective in treating

inflammation, unlike paracetamol, and they can be used to relieve pain without the side
effects of opioids (sedation, respiratory depression, high addiction rate).
D. Narcotic Analgesics
All opiate drugs belong to the last major class of drugs to be discussed, the
narcotics. Opiates have morphine-like action in the body whether they are synthetic or
occur naturally. As a class, they are currently the most effective painkillers, and in
addition to relieving pain, opiates produce a sense of well-being and euphoria (Meyer,
2005). These drugs have various side effects and at high doses, opiates can be lethal.
Opiates have been widely used for medicinal and recreational purposes for
centuries. The source of the opiates is opium, an extract of the poppy plant which
successfully grows in England and Denmark (Meyer, 2005). However, the opium poppy
is primarily cultivated in Southeast Asia, India, China, Iran, Turkey, and southeastern
Europe. Opium is prepared by collecting and drying the milky substance that pours from
the sliced seed capsules of the poppy Just before the plant ripens(Meyer, 2005).
Opium’s active ingredient is morphine (Fig. lA), but other constituents include,
thebaine and codeine (Katzung, 1998). Due to their effectiveness in treating pain,
pharmacologists have spent years modifying and synthesizing the active ingredients of
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opium in an attempt to minimize side effects, produce variations in potency, duration of
action, and oral effectiveness. Several semi-synthetic narcotics have been produced from
morphine and thebaine such as heroin and oxycodone, respectively (Katzung, 1998).
Other completely synthetic narcotics have been produced such as fentanyl, meperidine,
and methadone. Although several forms of the natural narcotics exist, all of them
produce the side effects commonly associated with moiphine (Meyer, 2005). Scientists
realized that since the body contained specific receptors that these drugs bind to, then the
body must also have endogenous ligands that bind to these receptors as well. This idea
led to the discovery of the endogenous opioids and their relationship with opiate receptor
subtypes(Meyer, 2005).
Endorphins, dynorphins, and enkephalins are the natural ligands that were
discovered that bind to opiate receptors (Minneman, 2005). Once in the brain, natural
narcotics and synthetic narcotics mimic these endogenous opioids by binding to opiate
receptors. Three important subtypes of opiate receptors have been characterized so far: \i
(mu),6(delta), and k (kappa)(Katzung, 1998).
The p-receptors have the highest affinity for the opiates. They are present
throughout the brain and spinal cord (Meyer, 2005). The areas of the brain abundant in
p-receptors play a role in morphine-induced analgesia (e.g., the medial thalamus,
periaqueductal gray, median raphe, and clusters within the spinal cord); positive
reinforcement (nucleus accumbens); cardiovascular and respiratory depression; cough
control; nausea and vomiting (brain stem); and sensorimotor integration (thalamus,
striatum)(Meyer, 2005).
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The 6-receptors are primarily found in the same areas of the brain as p-receptors
but are more restricted. They play a role in modulating olfaction, motor integration.
reinforcement, and cognitive function (Meyer, 2005). The regions of the brain rich in 6receptors are the neocoilex, striatum, olfactory areas, substantia nigra, and nucleus
accLimbens.

Overlapping of the 6-receptors and p-receptors suggests an analgesic

mechanism mediated both spinally and supraspinally (Meyer, 2005).
The K-receptors are even more restricted than the 6-receptors. They are found in
the striatum, amygdala, hypothalamus, and pituitary. These receptors modulate water
balance, temperature regulation, and neuroendocrine behavior and play a role in pain
perception, gut motility, and dysphoria (Meyer, 2005).
The endogenous ligands are able to bind to these receptors once the larger
peptides are cleaved (Meyer, 2005). Both biologically active and non-active opioid
peptides are released upon cleavage of the large peptides which are pro-opiomelanocortin
(POMC), prodynorphin, and proenkephalin (Meyer, 2005).

The biologically active

opioid peptides released are endorphins (mu receptor ligands), dynorphins (kappa
receptor ligands), and enkephalins (delta receptor ligands) (Minneman, 2005). These
large peptides are cleaved by proteases into smaller peptides that are packaged into
vesicles, transported down the axon, and released at the synapse (Meyer, 2005).
Once the smaller peptides are released at the synapse, they bind to their respective
receptor (Fig. 1), which is G protein linked (Katzung, 1998). Consequently, K'^ channels
open, Ca""^ channels close, and adenylyl cyclase activity is inhibited (Minneman, 2005).
At the cellular level, this results in a reduction in cell excitability, followed by inhibition
of cell firing, which ultimately leads to a decrease in the release of neurotransmitter. The
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neurotransmitters that would normally be released in response to pain include
norepinephrine, dopamine, and perhaps most importantly substance P and glutamate
(Sherwood, 2007).
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Figure 1 Opioid action at the cellular level. Opioids bind to the Gi protein linked
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Substance P is released from afferent pain fibers and activates ascending
pathways that send nociceptive signals to higher brain centers including the cortex (pain
localization), thalamus (pain perception), and the reticular formation (alertness). Other
areas, such as the hypothalamus and limbic system, which are both important in pain
perception, are indirectly affected by substance P(Sherwood, 2007).
Glutamate is released from primary afferent pain fibers and acts on dorsal horn
cell. It binds with AMPA receptors, which ultimately leads to the transmission of the
pain signals to higher brain centers. Glutamate also binds to NMDA receptors, which
leads to Ca""^ entry into the dorsal horn cell. As a result, second-messanger systems are
activated that make the cell more excitable, and this ultimately leads to a heightened
sensitivity to the injured area.
As stated previously, the natural and synthetic analgesics act in a similar way to
relieve pain. They reduce the transmission of the pain signals by inhibiting the spinal
projection neurons. This prevents pain perception at higher brain centers (supraspinally).
Opiates also modulate descending pathways that inhibit spinal cord transmission. These
pathways begin in the midbrain and change the pain signals relayed by spinal cord
signals. Descending pathways of significant importance begin in the Periaqueductal
Gray- an area rich in p and k receptors- and project to the medulla and brain stem.
Inhibition of the medulla and brain stem produces an additional analgesic effect because
their neurons descend into the spinal cord, ultimately inhibiting cell firing.
Narcotics inhibit pain more effectively than any of the other classes of analgesics,
however, the extent of their side effects limit their use. Less serious side effects include
nausea, vomiting, drowsiness, and constipation (Minneman, 2005). Serious side effects
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include respiratory depression, tolerance, dependency, and addiction (Minneman, 2005).
According to the National Institute on Drug Abuse, 4.7 million Americans used
prescription pain relievers nonmedically in 2005. This is an alarming statistic that
explains the need to discover drugs that are just as effective as narcotics in relieving pain,
but without the side effects. Hence, research efforts are ever increasing in search of
alternative sources, synthetic or natural, of potent analgesics. One natural source that
gained wide interest is the plant Mitragyna speciosa Korth.
E. Mitrcigynine
Mitragyna speciosa Korth (Rubiaceae) is a plant commonly found in Thailand
and other Southeast Asian countries. Natives traditionally used its leaves for their opium
like and coca-like stimulant effect to fight fatigue and improve tolerance to hard work
under the sun. The leaves have also been used as an opium substitute and for weaning
addicts off morphine (Matsumoto, 1996).
In the 1960’s, the Chelsea group in the U.K. isolated a significant number of
indole alkaloids from the plant species native to Thailand. Mitragynine (Fig. 2B) was
found to be the major constituent, accounting for 66.2% of the leaves constituents
(Takayama, 2004). A new alkaloid, 7, a-hydroxy-7H-mitragynine (Fig. 2C), was later
isolated as a minor constituent(2.0%)(Matsumoto, 1996).
Both mitragynine and 7, a-hydroxy-7H-mitragynine are thought to be responsible
for the plants’ antinociceptive activity, and both compounds demonstrate high selectivity
for the p-opioid receptor subtype (Matsumoto, 1996). It is believed that a supraspinal
opioid mechanism is partly involved in the analgesic activity of mitragynine (Takayama,
2004). In a study by Macko (1972), mitragynine suppressed the cough reflex, did not
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have an effect on the respiratory rate, and failed to produce toxicity at levels comparable
to those of opiates in three different species of animals (Macko, 1972). In much of the
previous research, the routes of administration of mitragynine were intraperitoneal (i.p.).
intracerbroventrical (i.c.v.), oral, and subcutaneous.

Interestingly, mitragynine is

structurally different from classical opioid receptor ligands and may provide lead
compounds that act as opioid analgesics without the traditional side effects associated
with opiates.
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Figure 2 The chemical structures of morphine (A), mitragynine (B), and 7, a-hydroxy7H-mitragynine (C).
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III.

SPECIFIC AIMS
The purpose of this study was to pharmacologically evaluate a series of

mitragynine analogs for their antinociceptive action in an effort to determine the
structural features responsible for analgesic activity. In a study by Takayama (2004),
researchers compai*ed the analgesic activity of morphine to the major and minor
constituents of Mitragyna speciosa Korth (Rubiaceae). In this study, two constituents.
mitragynine and 7, a-hydroxy-7H-mitragynine, significantly increased analgesic latency.
According to the results of the Takayama study, the analgesic activity of mitragynine was
Va the potency of morphine. However, 7, a-hydroxy-7H-mitragynine, an analog of
mitragynine, increased the analgesic latency nearly 13 times more than morphine.
Takayama concluded that addition and/or substitution of specific chemical groups on
mitragynine may increase the compounds analgesic potency. In the present study,
analogs of mitragynine were synthesized and tested in vivo to determine analgesic
activity. The analgesic activity or inactivity of these newly synthesized analogs may
suggest which chemical groups or atoms are necessary for mitragyine’s analgesic
potency.
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IV.

MATERIALS AND METHODS

A. Subjects
For all experiments, male Swiss Webster mice (25-30 g, Harlan, Indianapolis, IN,
USA) were used. The mice were housed in groups of five with a 12 h light/12 h dark
cycle. Food and water were provided ad libitum. All mice were randomly selected for
each treatment group (n = 10 per group). All procedures involving animals were
performed according to the guidelines approved by the Institutional Animal Care and Use
Committee.
B. Drugs
Morphine Sulfate was obtained from Sigma-Aldrich (St. Louis, MO, USA) and
was dissolved in saline (0.9% NaCl). Naloxone hydrocholride was obtained from Tocris
Bioscience (Ellisville, MO, USA)and was dissolved in saline (0.9% NaCl). Mitragynine
was isolated by Dr. Christopher McCurdy and Jessica Adkins at the Medicinal Chemistry
Department, School of Pharmacy, University of Missississippi, and was dissolved as the
hydrochloride salt in saline (0.9% NaCl). Compounds MCI83, MCI86, and MCI87
were synthesized by Dr. Christopher McCurdy and J. Cui and provided as hydrochloride
salts. Compound MCI83 was dissolved in 2% DMSO, and Compounds MCI86 and
MC187 were dissolved in (0.9% NaCl).
C. Tail-flick Studies
The tail-flick assay (Fig. 3) characterizes thermal nociception,

A tail-flick

apparatus that integrates thermal nociception and an automated response timer was used
(IITC Inc. Life Science, Woodland Hills, CA, USA). Mice were restrained individually

14

in a plexiglass restrainer, allowed to calm down for 1 minute, and the tail was positioned
in a groove that marks the position where a thermal stimulus is initiated. A timer was
started along with the onset of the stimulus. The timer automatically shuts off when the
animal flicks its tail. The mean of two trials measured 20-30s apart was taken for each
animal. A cut-off time of 15 s was used to minimize the risk of tissue damage. Animals
received either vehicle (saline or 2% DMSO), morphine (5, 10, 15, 20 mg/kg).
mitragynine (10, 20, 30 mg/kg), MC183(30 mg/kg), MC186(30 mg/kg), or MC187(30
mg/kg) intraperitoneally. Tailflick tests were then conducted at 0, 10, 20, 30, 60, and 120
min following drug administration. Measurements taken at time 0 were considered the
baseline latencies.
D. Hotplate Studies
The hotplate assay (Fig. 4) was used to assess thermal nociception at both spinal
and supraspinal levels. Twenty four hours prior to testing, mice received one apparatus
habituation trial (15 min) in which they are placed inside the acrylic enclosure with the
hotplate (lire Inc. Life Science, Woodland Hills, CA, USA) surface temperature
maintained at room temperature. Nociceptive tests (hotplate temperature = 52 °C) were
conducted with a manual timer started when all four paws of the animal made contact
with the hotplate floor. Latency to flutter or lick a hindpaw served as the nociceptive
measure. A 45 s cut-off time was used to minimize tissue damage. Baseline hotplate
latency was measured for each animal prior to drug administration.

Animals then

received either vehicle (saline or 2% DMSO), morphine (5, 10, 15, 20 mg/kg),
mitragynine (10, 20, 30 mg/kg), MCI83(30 mg/kg), MCI86(30 mg/kg), or MCI87(30
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mg/kg) intraperitoneally. Hotplate tests were then conducted at 10, 20, 30, 60, and 120
min following drug administration.
Animals pretreated with Naloxone had their baseline readings recorded first.
Following the baseline reading, the animals were injected with 10 mg/kg Naloxone and
given a 15 minute latency period. At 15 minutes, the animals were injected with
Morphine Sulfate (20 mg/kg) or Mitragynine (30 mg/kg) and given another 30 minute
latency period.

After this 30 minute latency period the final hotplate reading was

recorded.
Antinociception in hotplate and tailflick tests was quantified as the maximum
possible effect percent(MPE %)using the following formula:
%MPE=(postdrug latency)- (baseline latency) x 100
(cut off time)-(baseline latency)
E. Statistical Analysis
The data are expressed as the mean ± s.e.m. Statistical analysis was performed
using a one-way analysis of variance followed by Tukey’s test for multiple comparisons
or Dunnett’s test for vehicle control comparisons. The student t-test was used to compare
the groups pretreated with naloxone versus the morphine or mitragynine treated groups.
A p value < 0.05 was considered statistically significant for all analyses.
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Figure 3 Photograph of the tailflick apparatus.

Figure 4 Photograph of the hotplate apparatus.
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V.

RESULTS

Time and dose response curvesfor morphine in the tailflick and hotplate tests
As shown in Fig. 5A and Fig. 5B, when morphine (5-20 mg/kg) was administered
i.p., it significantly prolonged the nociceptive latency responses of the tailflick and
hotplate tests in mice. Increased latencies in both tests corresponded to increased doses.
Moiphine appeared to have its maximal effect at 60 minutes (20 mg/kg) in the tailflick
test and 30 minutes (20 mg/kg) in the hotplate test with a maximum %MPE of 83.04%
and 89.12%, respectively.
Time and dose response curvesfor niitragynine in the tailflick and hotplate tests
When niitragynine (10-30 mg/kg) was administered i.p., it did not significantly
prolong the nociceptive latency responses of the tailflick test in the mice, as shown in
Fig. 6A,

In contrast, mitragynine caused a significant dose-dependent increase in the

hotplate latency.

In the current study, the analgesic potency of the highest dose of

mitragynine (30 mg/kg, 53.10% MPE) was about one-half that of the highest dose of
morphine (20 mg/kg, 89.12% MPE) in the hotplate test. Again, the maximal effect of
mitragynine (30 mg/kg) was at 30 minutes.

Therefore, in Fig. 7, the nociceptive

responses of different doses at 30 minutes after i.p. administration of morphine and
mitragynine were compared in both tests.
Attenuation of antinociceptive action of morphine and mitragynine by naloxone
In Fig. 8, the antinociceptive actions of the i.p. injections of morphine (20 mg/kg)
observed in both the hotplate and tailflick tests were significantly attenuated by
pretreatment with naloxone (10 mg/kg), a preferential p-opioid antagonist (Takayama,
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2004). Naloxone also attenuated the antinociceptive effects of mitragynine (30 mg/kg) in
the hotplate test (shown in Fig. 9).
Evaluation of synthetic analogs of mitragynine in the tailflick and hotplate tests
As shown in Fig. 10-12, the synthetic analogs of mitragynine, MC183(30 mg/kg),
MCI86 (30 mg/kg), and MC187 (30 mg/kg) failed to show a significant increase in
tailflick or hotplate latencies when compared to mitragynine (30 mg/kg).
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The antinociceptive effects of Morphine (20 mg/kg i.p.) in the tailflick (A)

and hotplate (B) tests were blocked by pretreatment with the opioid receptor antagonist
Naloxone.

p< 0.001 versus morphine.
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200

Attenuation of Antinociceptive Action of 30 mg/kg Mitragynine by 10

mg/kg Naloxone.

The antinociceptive effects of Mitragynine in the tailflick (A) and

hotplate (B) tests were blocked by pretreatment with the opioid receptor antagonist
Naloxone. * p<0.05 versus mitragynine,

p< 0.001 versus mitragyine.
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(B) Tests. Compound MCI83 at 30 mg/kg did not show any analgesic effect in the
hotplate or tailflick assay. =
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VI.

DISCUSSION
Previous studies demonstrated an increase in latency in the tail-pinch and hotplate

tests after administration of mitragynine.

Also, it has been reported that 7-

hydroxymitragynine, which only differs from mitragynine by a hydroxyl group, has an
analgesic potency thirteen times that of morphine. Therefore, the purpose of this study
was to evaluate a series of mitragynine analogs for analgesic activity in an attempt to
determine the pharmocophoric groups responsible for action.
In the taiinick test, morphine (5- 20 mg/ kg i.p.) exerted a dose-dependent
increase in latency that reached its maximum activity at approximately 20-60 minutes
following the injection. In a study by Matsumoto (1996), morphine (1- 3 mg/ kg i.c.v.)
demonstrated dose-dependent antinociceptive activity that peaked approximately 15
minutes after the injection. The differences in the time at which maximum potency was
observed could be due to the administration routes as well as the doses. In the hotplate
test, morphine (5- 20 mg/ kg i.p.) demonstrated dose-dependent antinociceptive activity
that had a maximal effect at 20-60 minutes post injection. These findings are similar to
the findings published by Andoh (2007) in which single administration of morphine (1030 mg/ kg oral) dose-dependently inhibited thermal hyperalgesia and reached its maximal
effect at 30 minutes post injection. The opioid receptor antagonist, naloxone(10 mg/ kg),
significantly attenuated the antinociceptive activity of morphine in both the tailflick and
hotplate test, which corresponds to previously published data (Matsumoto, 1996;
Takayama, 2004).
In the present study, mitragynine (10- 30 mg/ kg i.p.) did not successfully lead to
an increase in antinociceptive activity in the tailflick test. These results were not typical
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of published literature on mitragynine. In a study by Matsumoto (1996), administration
of mitragynine (5- 30 mg/ kg) resulted in a dose-dependent increase in latency that
demonstrated a maximal effect at 15- 45 minutes following injection. These results
applied to both the tail-pinch and hotplate tests (Matsumoto, 1996). In this study, the
taiinick test was utilized as opposed to the tail-pinch test used by Matsumoto, and the
route of injection was i.p. as opposed to supraspinally in the Matsumoto study. Also, a
different mice strain was used in the present study, and these changes may account for the
differences in results. In addition, a higher dose of mitragynine should be examined to
determine if, in fact, it lacks activity in the tailflick test.
administration

of

mitragynine (10- 30

mg/ kg

In the hotplate test.

i.p.) exerted

dose-dependent

antinociceptive activity with a maximal effect at 20- 60 minutes after injection. These
findings agree with data published by Matsumoto (1996) in which mitragynine (5- 30
mg/ kg i.p.) demonstrated dose-dependent antinociceptive activity with a maximal effect
at 15- 45 minutes post injection. Also, pretreatment with the opioid receptor antagonist,
naloxone (10 mg/ kg i.p.), attenuated the antinociceptive activity in the tailflick and
hotplate tests. These results are in accordance with the data reported by Matsumoto et al.
(1996). However, it is important to note that naloxone was administered s.c. and i.c.v. in
the Matsumoto study. These findings indicate the involvement of opioid receptors in the
antinociceptive activity of mitragynine.
The analogs of mitragynine (Fig. 14) used in the present study were called
MC183, MC186, and MC187, and were synthesized by J. Cui under the direction of Dr.
Christopher McCurdy. In each of the structures, the 4-ring structure was compromised in
order to determine if it was essential for mitragynine’s analgesic activity. The analogs
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had not prev iously been synthesized or tested. Therefore, the dose administered in the
tail flick and hotplates tests was 30 mg/kg dose, which was the dose that was significantly
effective for mitragynine in the hotplate test. It is possible that these compounds could
have been effective at much higher doses.

However, at 30 mg/kg, the synthesized

compounds failed to show’ statistical significance in the tailflick or hotplate latencies
when compared to mitragynine (30 mg/kg). According to Takayama’s findings (2(X)4),
the methoxyl group at the C-9 position is required for antinociceptive activity. Also,
changing the functional group at this position shifted the activity of the compound from
an agonist to an antagonist (Takayama, 2004). In addition, Takayama concluded that the
Nb- lone electron pair was necessary for the antinociceptive activity of mitragynine.
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(A), MC186 (B), and 1V1C187 (C).
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VII.

CONCLUSION
In conclusion, the ring structure of mitragynine must remain intact if an analgesic

effect is desired. In a previous study conducted by Takayama (2004), it was suggested
that 7-hydroxymitragynine, which can be isolated from the plant or synthesized by the
addition of

hydroxyl group at the 7'^ carbon position of mitragynine, is in fact, the

active ingredient ol the plant. Like Macko (1972), Takayama (2004)reported fewer side
effects regardless ot the dose ot mitragynine as well as its derivatives. These results are
uncommon for opioid compounds.

Current findings suggest a positive future for

mitragynine in the development of new compounds to treat pain.

Future plans for

research include synthesizing 7-hydroxymitragynine, testing its antinociceptive activity
in the tailflick and hotplate assays, and determining its mechanism of action. After
comparing the results to those of morphine and mitragynine, additional tests could be
conducted to determine it the compound induces cocoa-like stimulant effects and other
possible side effects that are typical of opioids.
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